Systematic Financial Management LP Acquires 29,647 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Systematic Financial Management LP raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 283,977 shares of the specialty pharmaceutical company’s stock after buying an additional 29,647 shares during the quarter. Systematic Financial Management LP owned 0.47% of Jazz Pharmaceuticals worth $31,638,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Itau Unibanco Holding S.A. acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares in the last quarter. Gladius Capital Management LP acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Venturi Wealth Management LLC lifted its position in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,163 shares of company stock valued at $968,992. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $123.45 on Thursday. The business has a 50 day simple moving average of $115.69 and a 200 day simple moving average of $111.38. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $7.46 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 1.03 and a beta of 0.57.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada upped their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.